Article Text

Download PDFPDF
PostScript
Decline in the incidence of colorectal cancer and the associated mortality in young Italian adults
    1. 1 Veneto Tumour Registry, Azienda Zero, Padova, Italy
    2. 2 Chirurgia Generale e Specialistica, Vita-Salute San Raffaele University – Scientific Institute San Raffaele, Milano, Italy
    3. 3 Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy
    4. 4 Department of Diagnostic Sciences, University of Padova, Padova, Italy
    1. Correspondence to Manuel Zorzi, Veneto Tumour Registry, Azienda Zero, Padova 35132, Italy; manuel.zorzi{at}azero.veneto.it

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We have read with interest the article by Vuik et al that reported the trends in early-onset colorectal cancer (eoCRC) in 20 European countries.1 On the basis of data from nine of 20 Italian regions covering the years 1996–2009, Italy was the only European country where the incidence of eoCRC has dropped. This picture is supported by the latest findings based on cancer records covering almost 36 million Italian residents (60% of the population, almost 15 millions aged 20-49 years) in the data set as at 2014 of the Italian Association of Tumour Registries (AIRTum).2 This newly available information on the incidence of eoCRC and the corresponding mortality rates further confirms the peculiar favourable Italian trend.

    The present report concerns a total of 17 204 incident eoCRCs in patients aged 20–49 years registered between 2003 and 2014, with an overall incidence of 9.4/105 (males (M)=9.3/105; females (F)=9.4/105; figure 1). A declining incidence of eoCRC was documented during this period for the population as a whole (annual percent change (APC): −1.5%; 95% CI: −1.9 to −1.0), and in both sexes (M-APC: −1.6%; F-APC: −1.2%). The mortality rates (M=2.1/105; F=2.0/105; figure 1) also dropped in both males (APC: −1.9%) and females (APC: −2.3%). The eoCRC …

    View Full Text

    Footnotes

    • Collaborators AIRTUM Working Group (to be listed as authors): G Mazzoleni (Registro Tumori dell’Alto Adige), G Morrone (Registro Tumori Avellino), E Caputo (Registro Tumori di Bari), R Galasso (Registro Tumori Basilicata), A Citarella (Registro Tumori ASL Benevento), G Sampietro (Registro Tumori della ATS di Bergamo), M Magoni (Registro Tumori dell’ATS di Brescia), L Cavalieri d’Oro (Registro Tumori dell’ATS Brianza), A Ardizzone (Registro Tumori ASL Brindisi), A D’Argenzio (Registro Tumori ASL di Caserta), S Sciacca (Registro Tumori Integrato Catania - Messina - Enna), S Pisani (Registro Tumori dell’ATS dell’Insubria), P Ricci (Registro Tumori Cremona e Mantova), A Giorno (Registro Tumori Cosenza e Crotone), S Ferretti (Registro Tumori della Romagna, sede di Ferrara), F Palma (Registro Tumori della Provincia di Foggia), D Serraino (Registro Tumori del Friuli Venezia Giulia), S Iacovacci (Registro Tumori di Popolazione della Provincia di Latina), F Quarta (Registro Tumori della Provincia di Lecce), RA Filiberti (Registro Tumori Regione Liguria), S Vitarelli (Registro Tumori Marche), AG Russo (Registro Tumori dell’ATS di Milano), G Carrozzi (Registro Tumori di Modena), G D’Orsi (Registro Tumori ASL Napoli2 Nord), M Fusco (Registro Tumori Napoli3 Sud), GM Sini (Registro Tumori di Nuoro), F Vitale (Registro Tumori di Palermo e Provincia), M Michiara (Registro Tumori della Provincia di Parma), L Boschetti (Registro Tumori della Provincia di Pavia), G Chiaranda (Registro Tumori Piacenza), S Rosso (Registro Tumori Piemonte), R Tumino (Registro Tumori per le Province di Caltanissetta e Ragusa), L Mangone (Registro Tumori Reggiano), S Valenti Clemente (Registro Tumori Reggio Calabria), F Falcini (Registro Tumori della Romagna), AL Caiazzo (Registro Tumori di Popolazione della Asl Salerno), R Cesaraccio (Registro Tumori Sassari), A Madeddu (Registro Tumori di Siracusa), AC Fanetti (Registro Tumori di Sondrio), S Minerba (Registro Tumori di Taranto), A Caldarella (Registro Tumori Toscano), G Candela (Registro Tumori della Provincia di Trapani-Agrigento), S Piffer (Registro Tumori della Provincia di Trento), F Stracci (Registro Tumori Umbria), G Tagliabue (Registro Tumori della Provincia di Varese), M Rugge (Registro Tumori del Veneto), A Brustolin (Registro Tumori della Provincia di Viterbo), M Castelli (Registro Tumori della Regione Valle D’Aosta).

    • Contributors MZ and MR: study concept and design, interpretation of data, drafting of the manuscript; AWG: acquisition of data; SG: statistical analysis, interpretation of data; GMC and LDM: interpretation of data. All the authors: critical revision of the article for important intellectual content and final approval of the article.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.